- Home
- BWIV vs EQ Comparison
BWIV vs EQ Comparison
Compare BWIV & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWIV | EQ |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.1M | 157.4M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BWIV | EQ |
|---|---|---|
| Price | $9.90 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 18.8K | ★ 477.7K |
| Earning Date | N/A | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $0.76 |
| 52 Week High | $9.95 | $3.54 |
Technical Indicators
Market Signals| Indicator | BWIV | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 47.48 |
| Support Level | $9.90 | $1.97 |
| Resistance Level | N/A | $2.61 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 59.90 | 59.32 |
Price Performance
Historical ComparisonAbout BWIV Blue Water Acquisition Corp. IV Class A Ordinary Shares
Blue Water Acquisition Corp IV is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.